Polycystic Ovary Syndrome is the most common endocrine disorder in women, is estimated to affect more than 5% of the population and is associated with chronically elevated serum androgen concentrations.Evidence suggests that polycystic ovary syndrome has a negative impact on pregnancy outcomes, with an increased risk of gestational diabetes, hypertensive disease during pregnancy,and preterm birth,which is partially related with the hyperandrogenic environment.Diane-35 has been proved to be the most effective anti-androgenic drug.At present, there is no direct evidence that Diane-35 has a positive effect on the clinical outcome of polycystic ovary syndrome patients undergoing In-vitro fertilization/Intracytoplasmic sperm injection.

Inclusion Criteria:

• diagnosed polycystic ovary syndrome patients according to Rotterdam criteria
• with hyperandrogenism and/or clinical hyperandrogenic manifestations
• no other oral contraceptives treatment for at least 3 months before this experiment
• no any other assisted reproductive therapy
• accompanied with fallopian tube and/or male factors
• normal hepato-/nephro- function

Exclusion Criteria:

• oral contraceptive pills contraindications, eg.Deep Venous Thrombosis
• smoking, drunk
• exclude other infertile factors, eg.endometriosis, abnormal thyroid function, etc.